ArticlePloS one2026
Time to sputum culture conversion, treatment outcomes, and associated factors among rifampicin-resistant or multidrug-resistant tuberculosis patients in the Sidama region, Ethiopia: A retrospective follow-up study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTime to sputum culture conversion is critical for follow-up treatment effectiveness in multidrug-resistant tuberculosis patients. However, the evidence regarding time to culture conversion, treatment outcomes, and the associated factors was sparse and inconsistent.
objectiveThis study aimed to determine the time to culture conversion, treatment outcomes, and associated factors among rifampicin-resistant and multidrug-resistant tuberculosis cases in the Sidama region from April 1 to December 31, 2024.
methodsWe conducted a retrospective follow-up study of 346 patients who enrolled between January 2013 and June 2024. We collected data from patients' medical records using a standardized form, entered the data, and analyzed it using Stata 16.1 software. We performed the analysis using the Kaplan-Meier model for time to culture conversion, Weibull distribution gamma frailty, and logistic regression models to assess factors associated with time to culture conversion and treatment outcomes, respectively. We considered an adjusted hazard or odds ratio with a 95% CI and a p-value < 0.05 to determine significance.
resultsAmong the participants, 302 (87.3%) achieved culture conversion in a median time of 76 days (95% CI: 71-79 days). Patients with a history of previous loss to follow-up experienced an approximately fivefold delay in culture conversion (AHR = 0.2; 95% CI: 0.1-0.6; p = 0.001), while relapse cases had a twofold delay (AHR = 0.5; 95% CI: 0.2-0.9; p = 0.02) compared with new patients. The treatment success rate was 234/346 (67.6%). Female patients had higher odds of achieving a favorable treatment outcome (AOR = 1.8; 95% CI: 1.0-3.3; p = 0.04), whereas patients who experienced culture reversion had significantly lower odds of a favorable outcome (AOR = 0.05; 95% CI: 0-0.4; p = 0.001).
conclusionsThe majority of patients experienced culture conversion within three months. However, patients with a history of loss to follow-up and relapse experienced delayed culture conversion. These findings highlight the urgent need to improve patient adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.